...
首页> 外文期刊>Daru Journal of pharmaceutical sciences. >A new strategy based on pharmacophore-based virtual screening in adenosine deaminase inhibitors detection and in-vitro study
【24h】

A new strategy based on pharmacophore-based virtual screening in adenosine deaminase inhibitors detection and in-vitro study

机译:一种基于药效团虚拟筛选的腺苷脱氨酶抑制剂检测和体外研究新策略

获取原文

摘要

Background and the purpose of the study Adenosine deaminase (ADA) inhibition not only may be applied for the treatment of ischemic injury, hypertension, lymphomas and leukaemia, but also they have been considered as anti- inflammatory drugs. On the other hand according to literatures, ADA inhibitors without a nucleoside framework would improve pharmacokinetics and decrease toxicity. Hence we have carried out a rational pharmacophore design for non-nucleoside inhibitors filtration. Methods A merged pharmacophore model based on the most potent non-nucleoside inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and natural products were generated and applied for compounds filtration. The effects of filtrated compounds based on pharmacophore and docking studies investigated on ADA by UV and Fluorescence spectroscopy techniques. Results Extracted compounds were find efficiently inhibit ADA, and the most potent ( 2 ) shows an inhibition constant equal to 20 μM. Besides, Fluorescence spectroscopy studies revealed that enzyme 3D structure bear further change in lower concentrations of compound 2 . Conclusion 3 non-nucleoside inhibitors for ADA are presented. According to obtained results from UV and fluorescence spectroscopy, such interesting pharmacophore template with multiple approaches will help us to extract or design compound with desired properties.
机译:研究背景和目的抑制腺苷脱氨酶(ADA)不仅可用于治疗缺血性损伤,高血压,淋巴瘤和白血病,而且已被认为是抗炎药。另一方面,根据文献,没有核苷骨架的ADA抑制剂将改善药代动力学并降低毒性。因此,我们为非核苷抑制剂的过滤进行了合理的药效团设计。方法建立了基于最有效的非核苷类抑制剂erythro-9-(2-羟基-3-壬基)腺嘌呤(EHNA)和天然产物的合并药效团模型,并将其用于化合物过滤。基于药效基团和对接研究的滤液化合物的影响,通过紫外和荧光光谱技术在ADA上进行了研究。结果发现提取的化合物可有效抑制ADA,最有效的(2)显示出等于20μM的抑制常数。此外,荧光光谱研究表明,酶3D结构在较低浓度的化合物2中具有进一步的变化。结论提出了3种ADA的非核苷抑制剂。根据从紫外和荧光光谱获得的结果,这种有趣的具有多种方法的药效团模板将帮助我们提取或设计具有所需特性的化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号